Fundamental analysis · SEC EDGAR · as of 31/03/2026
MCK · NYSE · Healthcare
Fundamental quality
62
out of 100
McKesson Corp earns a fundamental-quality score of 62 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its growth (revenue +11.1%/yr). Its weakest area is its profitability (net margin 1.2%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
McKesson is the largest U.S. drug distributor: the logistics middleman moving medicines from drugmakers to pharmacies and hospitals. A business of gigantic volumes and razor-thin margins, but very stable: it's a three-player oligopoly.
EPS growth: 43.8% · Revenue growth: 11.1%
Net margin: 1.2%
Net debt/EBITDA: 0.39x · FCF: 1.4%
Source: SEC EDGAR · as of 31/03/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | 238,228 | -4,539 | 4,091 | 822 |
| 2022 | 263,966 | 1,114 | 4,046 | 2,368 |
| 2023 | 276,711 | 3,560 | 4,769 | 922 |
| 2024 | 308,951 | 3,002 | 3,883 | 1,046 |
| 2025 | 359,051 | 3,295 | 5,548 | 9 |
| 2026 | 403,430 | 4,762 | 5,719 | 2,551 |
Between 2021 and 2026, revenue went from $238,228M to $403,430M (+69%) and net income went from -$4,539M to $4,762M (+205%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
$0.72
per share, yearly
8% of earnings
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is McKesson Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is McKesson Corp a good company to invest in?
In terms of business quality, McKesson Corp scores 62 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is McKesson Corp a profitable company?
McKesson Corp is profitable, with a net margin of 1.2%, though a thin one.
Does McKesson Corp have a lot of debt?
Not particularly. Its net debt is 0.39 times its EBITDA, a low level.
Is McKesson Corp growing?
Its revenue has grown 11.1% annualized in recent years and its earnings per share 43.8%, and without interruption since 2021.
Does McKesson Corp generate cash?
Yes. It converts about 1.4% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Brightspring Health Services (BTSG) · Community Health Systems (CYH) · Hims & Hers Health (HIMS) · Oscar Health (OSCR) · Recursion Pharmaceuticals (RXRX) · Eli Lilly (LLY) · see more →
Who's behind the methodology and model · how the score is computed
Data: see McKesson Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.